Shi Yuankai, He Xiaohui, Yang Sheng, Ai Bin, Zhang Changgong, Huang Dingzhi, Dong Mei, Liu Peng, Zhou Shengyu, Han Xiaohong
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chemotherapy. 2007;53(1):44-50. doi: 10.1159/000098418. Epub 2007 Jan 3.
This study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side effects caused by cisplatin-containing chemotherapy.
Fifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0.3 mg of ramosetron and 16 mg of ondansetron in a prospective crossover comparison study.
Data were collected for analysis of the therapeutic effect in 47 cases and for adverse events in 50 cases. Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss. From days 3-5, ramosetron tended to be more effective than ondansetron in its antiemetic action. The incidence of headache, fatigue and constipation was the same for both drugs.
Ramosetron is a long-lasting and safe antiemetic agent.
本研究观察并比较了雷莫司琼和昂丹司琼对含顺铂化疗引起的胃肠道副作用的预防效果。
在一项前瞻性交叉比较研究中，将50例首次接受化疗的恶性肿瘤患者随机分为两组，每组分别接受0.3毫克雷莫司琼和16毫克昂丹司琼。
收集了47例患者的治疗效果数据和50例患者的不良事件数据进行分析。两种药物在化疗引起的胃肠道副作用、第1天的呕吐和食欲减退方面表现相似，但到第5天，雷莫司琼在控制食欲减退方面明显优于昂丹司琼。在第3 - 5天，雷莫司琼的止吐作用倾向于比昂丹司琼更有效。两种药物的头痛、疲劳和便秘发生率相同。
雷莫司琼是一种长效且安全的止吐药物。
